tradingkey.logo

BUZZ-Charles River Lab falls after company's 2025 revenue forecast

ReutersJan 14, 2025 2:06 PM

Contract research firm Charles River Laboratories' CRL.N shares fall 11.1% to $169.01 premarket

Company forecasts 2025 revenue will decline organically in a similar range as estimated in 2024

Charles River in November forecast full-year 2024 revenue to decrease 2% to 3%, versus previous expectations of it falling 2.5% to 4.5%

Company says lower commercial contract drug manufacturing revenue is expected to "reduce consolidated revenue growth by approximately 1% in 2025"

Charles River says a cell therapy client notified CRL that it would terminate its commercial agreement with the company "to utilize another long-time CDMO partner"

Company adds that cell and gene therapy client demand "is not as robust as at the time of acquisition, but attractive, long-term growth opportunities exist for its CDMO business"

Stock fell 21.9% in 2024

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI